HOME >> MEDICINE >> NEWS
Specialty medical societies offer evidence-based conclusions on inhaled steroid treatment for asthma

(NORTHBROOK, IL, December 9, 2003) - Inhaled corticosteroid (ICS) therapy remains the gold standard of asthma treatment, according to findings from a systematic evidence review released today by the American College of Chest Physicians (ACCP), the American Academy of Allergy, Asthma, and Immunology (AAAAI), and the American College of Allergy, Asthma, and Immunology (ACAAI). Published in the December issue of CHEST, the peer-reviewed journal of the ACCP, the review offers evidence-based conclusions on several prominent risks associated with ICS therapy for the treatment of adult and pediatric asthma.

"ICS therapy has been the gold standard in asthma treatment for 20 years because of its proven effectiveness. However, since the inception of ICS therapy, physicians have been concerned about side effects, particularly in special populations, such as children, women, and the elderly," said lead author Frank T. Leone, MD, MS, FCCP, Thomas Jefferson University, Philadelphia, PA. "After a systematic and accurate review of the proven risks, we can say with confidence that the majority of evidence supports the conclusion that the clinical effectiveness of ICS therapy decidedly outweighs the proven risks."

An expert panel with representatives from the ACCP, the AAAAI, and the ACAAI identified critical questions that impact decisions regarding the use of ICS therapy in relation to the five adult and pediatric risk areas of bone mineral density (BMD), cataracts, glaucoma, growth retardation, and skin thinning. Panel members reviewed 108 asthma studies related to ICS therapy complications and summarized all relevant evidence for each risk area. A consensus statement was provided for each risk area along with a grade to reflect the quantity and quality of evidence supporting each conclusion. Overall, the panel concluded that the benefits associated with ICS use greatly exceed the risks. In regards to the effect of ICS therapy on BMD, the panel stro
'"/>

Contact: Jennifer Stawarz
jstawarz@chestnet.org
847-498-8306
American College of Chest Physicians
8-Dec-2003


Page: 1 2

Related medicine news :

1. Rigorous Evaluation Of "Hospitalist" Model Needed To Determine Impact Of This New Medical Specialty, According To UCSF Health Policy Researchers
2. Advertising by academic medical centers may risk eroding public trust, says study
3. NIH state-of-the-science panel calls for demedicalization of menopause
4. Community care tops medical care at preventing heart disease in black Americans
5. Breakthrough in medical research: New chemotherapy gives hope to brain tumour patients
6. Jefferson Lab medical imager spots breast cancer
7. Society of Hospital Medicine to launch new medical journal
8. LA BioMed medical/research briefs March 2005
9. Promising new strategy for Swedish medical research
10. Flu vaccination benefits people of any age with high-risk medical conditions
11. UCLA study: Nearly a third of drug ads in medical journals contain no references for medical claims

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:6/27/2016)... CA (PRWEB) , ... June 27, 2016 , ... ... College District , the only authorized OSHA Training Institute Education Center headquartered in ... by protecting their workers from extreme heat at their worksites. Employers with ...
(Date:6/27/2016)... ... 27, 2016 , ... "FCPX editors can now reveal their media with growing ... said Christina Austin - CEO of Pixel Film Studios. , ProSlice Color brings ... users can now reveal the media of their split screens with growing colorful panels. ...
(Date:6/27/2016)... ... June 27, 2016 , ... TherapySites, the ... affiliation with Tennessee Counseling Association. This new relationship allows TherapySites to ... Counseling Association, adding exclusive benefits and promotional offers. , "TCA is extremely excited ...
(Date:6/27/2016)... ... June 27, 2016 , ... ... its strategic partnership with Connance, a healthcare industry leader providing predictive analytics ... proprietary technology combine to provide health systems, hospitals and ambulatory surgical centers ...
(Date:6/27/2016)... ... June 27, 2016 , ... A ... revolutionize the emergency ambulance transport experience for the millions of people who require ... has disrupted the taxi industry through the use of technology. Now, SmartEMS has ...
Breaking Medicine News(10 mins):
(Date:6/26/2016)... SYDNEY , June 26, 2016 One of ... , has announced the formation of a new biotechnology company, Noxopharm ... raise $6m in an IPO and to list on the ASX. ... drug candidate, NOX66, ready to enter a Phase 1 clinical study ... been designed to address one of the biggest problems facing cancer ...
(Date:6/26/2016)... DUBLIN , June 27, 2016 Jazz ... the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act ... proposed acquisition of Celator Pharmaceuticals, Inc. ("Celator"; Nasdaq: ... 11:59 p.m. (Eastern Daylight Time). As previously ... entered into a definitive merger agreement under which Jazz ...
(Date:6/26/2016)... OTTAWA, Ontario , June 27, 2016  VMS ... the Company,s Board will take whatever measures required to ... the Company,s stock which is currently listed on the ... S Wexler, Company Chairman and CEO, "We are seeing ... be difficult to understand, not only by the Company, ...
Breaking Medicine Technology:
Cached News: